Clearant Sterilization Method Aimed At Musculoskeletal Tissue Processors
This article was originally published in The Gray Sheet
Executive Summary
Clearant, Inc. is looking to develop licensing agreements for its Clearant sterilzation process with a number of tissue processing companies in the coming year, addressing a $650-750 mil. U.S. musculoskeletal tissue market
You may also be interested in...
Cryolife
CDC confirms presence of rare bacterium Clostridium sordellii in Cryolife-processed human donor condyle tissue implanted in a 23-year old Minnesota knee surgery patient who died Nov. 11; the bacterium was not found or implicated in two other Minnesota total knee replacement patient deaths. Cryolife does not intend to alter its processing protocols after CDC, FDA and the Minnesota Department of Health found no connection between the deaths and made no recommendations for changes (1"The Gray Sheet" Dec. 10, 2001, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.